Enliven Therapeutics, Inc. (ELVN)
(Delayed Data from NSDQ)
$27.31 USD
+2.29 (9.15%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $27.24 -0.07 (-0.26%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Income Statements
Fiscal Year end for Enliven Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 84 | -1 | 51 | 42 | 24 |
Income After Depreciation & Amortization | -84 | 1 | -51 | -42 | -24 |
Non-Operating Income | 12 | 1 | 0 | 0 | 1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -72 | 2 | -51 | -41 | -23 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -72 | 1 | -51 | -41 | -23 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -72 | 1 | -51 | -41 | -23 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -88 | 1 | -51 | -41 | -24 |
Depreciation & Amortization (Cash Flow) | -4 | 1 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -84 | 1 | -51 | -42 | -24 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 35.55 | 6.60 | 5.42 | 3.48 | NA |
Diluted EPS Before Non-Recurring Items | -2.01 | 0.24 | -9.48 | -14.12 | NA |
Diluted Net EPS (GAAP) | -2.01 | 0.24 | -9.48 | -14.12 | NA |
Fiscal Year end for Enliven Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 25.99 | 22.72 | 24.25 | 20.13 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -25.99 | -22.72 | -24.25 | -20.13 |
Non-Operating Income | NA | 3.25 | 3.36 | 3.48 | 3.41 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -22.74 | -19.37 | -20.77 | -16.72 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -22.74 | -19.37 | -20.77 | -16.72 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -22.74 | -19.37 | -20.77 | -16.72 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 42.05 | 41.13 | 41.03 | 40.96 |
Diluted EPS Before Non-Recurring Items | NA | -0.54 | -0.47 | -0.51 | -0.41 |
Diluted Net EPS (GAAP) | NA | -0.54 | -0.29 | -0.51 | -0.41 |